Cargando…
Unblinding at disease progression in double-blinded randomized controlled cancer drug clinical trials: A controversy requires more attention
Unblinding at disease progression in double-blinded randomized controlled cancer drug clinical trials is ethical to the patient by ensuring optimal subsequent treatment, but the effect of study treatment on overall survival may be confounded. The views of science and ethics in this issue are controv...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792660/ https://www.ncbi.nlm.nih.gov/pubmed/36582284 http://dx.doi.org/10.3389/fmed.2022.1082445 |